[Purpose] The aim of the present study was to establish up-to-date data regarding the lung function of cystic fibrosis (CF) patients. [Subjects and Methods] Forty-eight patients of both genders, with a diagnosis of CF, were recruited. As a result our sample presented, according to the GOLD criteria, 23 patients with mild lung obstruction (FEV1%pred: 89.86), 16 patients with moderate lung obstruction (FEV1%pred: 56.1) and 9 patients with severe obstruction (FEV1%pred: 32.1). [Results] All patients presented normal total lung capacity followed by an important residual volume increase. [Conclusion] Our results were important to illustrate the CF patient's lung functional status and to improve the health system strategy in treating such individuals.
[Purpose] The aim of the present study was to establish up-to-date data regarding the lung function of cystic fibrosis (CF) patients. [Subjects and Methods] Forty-eight patients of both genders, with a diagnosis of CF, were recruited. As a result our sample presented, according to the GOLD criteria, 23 patients with mild lung obstruction (FEV1%pred: 89.86), 16 patients with moderate lung obstruction (FEV1%pred: 56.1) and 9 patients with severe obstruction (FEV1%pred: 32.1). [Results] All patients presented normal total lung capacity followed by an important residual volume increase. [Conclusion] Our results were important to illustrate the CF patient's lung functional status and to improve the health system strategy in treating such individuals.
Cystic fibrosis (CF) is a recessive disorder caused by genetic mutations. The prevalence in
Europe is 0.737 per 10,000 and the incidence rate in Italy is estimated at 1/3,000 live
births1). It is associated with early
airway inflammation with both functional and structural consequences2, 3). Over the last 2–3
decades, the CF has evolved from an acute disease of childhood into a chronic disease of
adulthood4). It is known that over half
of all CF patients are now over the age of 18, and those patients are able to survive for
many years despite their profoundly damaged lungs and reduced lung function5). In Italy the CF prevalence over 10,000
subjects is 0.8726). Considering the
importance of establishing up-to-date data regarding this disease, we designed a prospective
study to assess the lung function of CF patients treated in our regional cystic fibrosis
center.
SUBJECTS AND METHODS
From May to September 2011 at the Centro Regionale Cystic Fibrosis in
Cesena we evaluated the lung function of 48 CF patients (22 females) aged 21 ± 3. The tests
were performed according to ATS/ERS guidelines for spirometry and lung volumes
assessments7, 8). As a result our sample presented, according to the GOLD criteria,
23 patients with mild lung obstruction (FEV1%pred: 89.86), 16
patients with moderate lung obstruction (FEV1%pred: 56.1) and 9
patients with severe obstruction (FEV1%pred: 32.1). Informed
consent was obtained from all participants and procedures were conducted according to the
Declaration of Helsinki.
RESULTS
All patients presented normal total lung capacity followed by an important residual volume
increase, also demonstrating a moderate to very severe lung hyperinflation besides the
airway obstruction. On the studied sample, the lung function loss is similar to those
described for the population with cystic fibrosis5) (Table 1).
Table 1.
Anthropometric data
Variable
Moderate COPD (n=23)
Severe COPD (n=16)
Very Severe COPD (n=9)
Antrophometric data
Gender [male, n (%)]
12 (47.8%)
9 (43.8%)
8 (88.9%)
Age (yrs)
19.2
25.1
21.0
Weight (kg)
47.1
50.1
47.3
High (cm)
155
160
151
BMI (kg.m–2)
19.6
19.6
20.8
Spirometry
FEV1 %pred
85.86
56.10
32.10
TLC %pred
100.17
103.35
100.28
RV %pred
138.37
195.46
268.94
RV/TLC (%)
135.37
185.53
256.53
Statistical differences are lacking in some lines.
Statistical differences are lacking in some lines.
DISCUSSION
Over the past six decades, an impressive improvement in survival has been achieved and the
CF population growth projection demonstrated an increase by 20% in children and by 78% in
adults6). Thus data like ours are
important to illustrate the CF patient’s lung functional status and improve the health
system strategy in treating such individuals.
Authors: R Pellegrino; G Viegi; V Brusasco; R O Crapo; F Burgos; R Casaburi; A Coates; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D C Johnson; N MacIntyre; R McKay; M R Miller; D Navajas; O F Pedersen; J Wanger Journal: Eur Respir J Date: 2005-11 Impact factor: 16.671
Authors: J Wanger; J L Clausen; A Coates; O F Pedersen; V Brusasco; F Burgos; R Casaburi; R Crapo; P Enright; C P M van der Grinten; P Gustafsson; J Hankinson; R Jensen; D Johnson; N Macintyre; R McKay; M R Miller; D Navajas; R Pellegrino; G Viegi Journal: Eur Respir J Date: 2005-09 Impact factor: 16.671
Authors: Helen E Jo; Tamera J Corte; Stephen J Wort; Neil D Eves; Amanda Piper; Claire Wainwright Journal: Respirology Date: 2016-02-24 Impact factor: 6.424
Authors: Pierre-Régis Burgel; Gil Bellis; Hanne V Olesen; Laura Viviani; Anna Zolin; Francesco Blasi; J Stuart Elborn Journal: Eur Respir J Date: 2015-03-18 Impact factor: 16.671
Authors: Fernando Silva Guimarães; Agnaldo José Lopes; Vanessa Joaquim Ribeiro Moço; Felipe Cavalcanti de Souza; Sara Lúcia Silveira de Menezes Journal: J Phys Ther Sci Date: 2014-06-30